InsiderSignal.AI

InsiderSignal.ai

PCRX - Pacira Biosciences, Inc.

Insider Sale by Cross Shawn (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Cross Shawn, serving as CFO at Pacira Biosciences, Inc. (PCRX), sold 12,941 shares at $25.16 per share, for a total transaction value of $325,596.00. Following this transaction, Cross Shawn now holds 105,341 shares of PCRX.

This sale represents a 11.00% decrease in Cross Shawn's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, April 23, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 24, 2026, 1 day after the trade was made.

Pacira Biosciences, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Cross Shawn

Cross Shawn

CFO

Shawn Cross is the Chief Financial Officer of Pacira BioSciences, Inc., a biopharmaceutical company specializing in non-opioid pain therapies[[3]](https://www.pharmafocus.com/articles/shawn-cross-appointed-as-chief-financial-officer-for-pacira-bios-f0ba). Appointed to the role in October 2024[[2]](https://www.insidertrades.com/pacira-biosciences-inc-stock/shawn-cross-1/), Cross brings over 25 years of experience in the biotechnology industry, investment banking, and corporate leadership[[4]](https://www.citybiz.co/article/615103/pacira-biosciences-appoints-shawn-cross-as-chief-financial-officer/). He holds a B.S. in Kinesiology from UCLA and an M.B.A. from Columbia Business School[[4]](https://www.citybiz.co/article/615103/pacira-biosciences-appoints-shawn-cross-as-chief-financial-officer/). Prior to joining Pacira, Cross served in senior leadership roles at Applied Molecular Transport (AMT), initially as Chief Financial Officer and leading the company through its initial public offering, then advancing to President and Chief Operating Officer, and ultimately to Chief Executive Officer[[4]](https://www.citybiz.co/article/615103/pacira-biosciences-appoints-shawn-cross-as-chief-financial-officer/). He led AMT through its merger with Cyclo Therapeutics, where he continues to serve on the Board of Directors[[2]](https://www.insidertrades.com/pacira-biosciences-inc-stock/shawn-cross-1/). Before his executive tenure, Cross spent over 20 years as an investment banker focused on the biopharmaceutical sector, serving as Managing Director of Healthcare Investment Banking at JMP Securities and holding senior positions at Deutsche Bank Securities and Wells Fargo Securities[[2]](https://www.insidertrades.com/pacira-biosciences-inc-stock/shawn-cross-1/)[[4]](https://www.citybiz.co/article/615103/pacira-biosciences-appoints-shawn-cross-as-chief-financial-officer/). He also serves as an Independent Director of BioPlus Acquisition Corp.[[1]](https://in.marketscreener.com/insider/SHAWN-CROSS-A11584/)

View full insider profile →

Trade Price

$25.16

Quantity

12,941

Total Value

$325,596.00

Shares Owned

105,341

Trade Date

Thursday, April 23, 2026

2 days ago

SEC Filing Date

Friday, April 24, 2026

Filed 1 day after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Pacira Biosciences, Inc.

Company Overview

No company information available
View news mentioning PCRX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5913454

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime